Litcius/Paper detail

COVID-19 in multiple sclerosis: The Dutch experience

Floor C. Loonstra, Elske Hoitsma, Zoé L. E. van Kempen, Joep Killestein, Jop Mostert

2020Multiple Sclerosis Journal78 citationsDOIOpen Access PDF

Abstract

Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed.

Topics & Concepts

Multiple sclerosisCoronavirus disease 2019 (COVID-19)MedicineNeurologyIntensive care unitDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakPediatricsInternal medicineInfectious disease (medical specialty)PathologyOutbreakImmunologyPsychiatryMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19